510584

research-article2014

JRA0010.1177/1470320313510584Journal of the Renin-Angiotensin-Aldosterone SystemWoo et al.

Original Article

Aliskiren and losartan trial in non-diabetic chronic kidney disease

Journal of the Renin-AngiotensinAldosterone System 2014, Vol. 15(4) 515­–522 © The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1470320313510584 jra.sagepub.com

Keng-Thye Woo1, Hui-Lin Choong1, Kok-Seng Wong1, Han-Kim Tan1, Marjorie Foo1, Stephanie Fook-Chong3, Evan JC Lee2, Vathsala Anantharaman2, Grace SL Lee1 and Choong-Meng Chan1

Abstract Introduction: This is a report of a clinical trial on the therapeutic efficacy and safety of combined aliskiren and losartan (an angiotensin II receptor blocker (ARB)) versus aliskiren alone and ARB alone in non-diabetic chronic kidney disease (CKD) over a 3-year period. Materials and methods: This was a randomised trial in 155 patients with non-diabetic CKD comparing aliskiren (150 mg/day) (n=52) versus losartan (100 mg/day) (n=52) and the third group aliskiren (150 mg/day) combined with losartan (100 mg/day) (n=51). The trial utilised primary renal end points of eGFR